Esperion Therapeutics Inc. NASDAQESPR added $2.58 11 to $27 on Thursday in the wake of positive Phase IIb results for the company's cholesterollowering molecule ETC1002 in patients with hypercholesterolemia with or without statin intolerance. The company a...
↧